Premium
Nanotherapy in Joints: Increasing Endogenous Hyaluronan Production by Delivering Hyaluronan Synthase 2
Author(s) -
Li Huimin,
Guo Huilin,
Lei Chang,
Liu Li,
Xu Liqin,
Feng Yaping,
Ke Jin,
Fang Wei,
Song Hao,
Xu Chun,
Yu Chengzhong,
Long Xing
Publication year - 2019
Publication title -
advanced materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.707
H-Index - 527
eISSN - 1521-4095
pISSN - 0935-9648
DOI - 10.1002/adma.201904535
Subject(s) - hyaluronic acid , osteoarthritis , endogeny , hyaluronan synthase , inflammation , temporomandibular joint , materials science , pharmacology , medicine , pathology , anatomy , alternative medicine
Osteoarthritis (OA) is a common joint degenerative disease that causes pain, joint damage, and dysfunction. External hyaluronic acid (HA) supplement is a common method for the management of osteoarthritis which requires multi‐injections. It is demonstrated that biodegradable mesoporous silica nanoparticles successfully deliver an enzyme, hyaluronan synthase type 2 (HAS2), into synoviocytes from the temporomandibular joint (TMJ) and generate endogenous HA with high molecular weights. In a rat TMJ osteoarthritis inflammation model, this strategy promotes endogenous HA production and inhibits the synovial inflammation of OA for more than 3 weeks with one‐shot administration. Such nanotherapy also helps repairing the bone defects in a rat OA bone defect model.